FORTUNE and Great Place to Work Name Second Genome a "Top 10 Best Workplace in Biopharma"

April 10, 2019, South San Francisco, CA

Read More

Second Genome Expands Development of CNS Platform to Validate Microbial Products as Therapeutics for Autism Spectrum Disorder

March 26, 2019, South San Francisco

Read More

Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)

January 23, 2019, South San Francisco

Read More

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer

September 26, 2018, South San Francisco, CA

Read More

Second Genome Certified as Great Place to Work®

July 31, 2018, South San Francisco, July 30, 2018

Read More

Second Genome Appoints Anupama S. Hoey as Chief Business Officer

July 23, 2018, South San Francisco, July 23, 2018

Read More

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

April 9, 2018, SOUTH SAN FRANCISCO, Calif.

Read More

Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer

March 5, 2018, South San Francisco, CA March 5, 2018

Read More